AUB ScholarWorks

Involvement of the α7-nicotinic acetylcholine receptors in the anti-inflammatory action of the thymulin-related peptide (PAT)

Show simple item record

dc.contributor.author Safieh-Garabedian B.
dc.contributor.author Oz M.
dc.contributor.author Bey R.M.
dc.contributor.author Shamaa F.
dc.contributor.author Ashoor A.
dc.contributor.author El-Agnaf O.M.
dc.contributor.author Saade N.E.
dc.contributor.editor
dc.date Oct-2013
dc.date.accessioned 2017-09-07T07:00:00Z
dc.date.available 2017-09-07T07:00:00Z
dc.date.issued 2013
dc.identifier 10.1016/j.neuroscience.2013.07.031
dc.identifier.isbn
dc.identifier.issn 03064522
dc.identifier.uri http://hdl.handle.net/10938/11232
dc.description.abstract Background and Purpose: Peptide analog of thymulin (PAT) has been shown to have anti-hyperalgesic and anti-inflammatory properties in animal models of inflammation. Recent reports suggest that the peripheral cholinergic system has an anti-inflammatory role mediated by α7-nicotinic acetylcholine receptor (α7-nAChR). Our aim is to investigate whether the action of PAT is mediated, via the cholinergic pathway. Experimental Approach: The anti-hyperalgesic and anti-inflammatory action of PAT was assessed in rat models of inflammatory nociceptive hyperactivity (carrageenan and endotoxin) and in a mice air-pouch model for localized inflammation, respectively; the possible attenuation of PAT's effects by pretreatment with the α7-nAchR specific antagonist methyllycaconitine citrate (MLA) was also investigated. In another series of experiments, using two electrode recordings, the effect of PAT on the α7-nAChRs, expressed in Xenopus Oocytes, was also determined. Key Results: Administration of PAT reversed inflammatory nociceptive hyperactivity and cold and tactile hyperactivity in rats. This effect was partially or totally prevented by MLA, as assessed by different behavioral pain tests. Treatment with PAT also reduced the alteration of cytokines and NGF levels by carrageenan injection in the mouse air pouch model; this effect was partially antagonized by MLA. Electrophysiological recording demonstrated that PAT significantly potentiated the α7-nAchR expressed in Xenopus Oocytes. These effects were not observed when a control peptide, with a reverse sequence (rPAT), was utilized. Conclusions and Implications: The behavioral and electrophysiological observations described in this report demonstrate that PAT mediates, at least partially, its anti-inflammatory action by potentiating the α7-nAChR. These results indicate that PAT has a potential for new therapeutic applications as anti-inflammatory and analgesic agent. © 2013 IBRO.
dc.format.extent
dc.format.extent Pages: (455-466)
dc.language English
dc.publisher OXFORD
dc.relation.ispartof Publication Name: Neuroscience; Publication Year: 2013; Volume: 250; Pages: (455-466);
dc.relation.ispartofseries
dc.relation.uri
dc.source Scopus
dc.subject.other
dc.title Involvement of the α7-nicotinic acetylcholine receptors in the anti-inflammatory action of the thymulin-related peptide (PAT)
dc.type Article
dc.contributor.affiliation Safieh-Garabedian, B., Department of Natural Sciences and Public Health, Zayed University, Abu Dhabi, United Arab Emirates
dc.contributor.affiliation Oz, M., Functional Lipidomics Branch, Department of Pharmacology, Faculty of Medicine and Health Sciences, UAE University, Al Ain, United Arab Emirates
dc.contributor.affiliation Bey, R.M., Department of Anatomy, Cell Biology and Physiology, Faculty of Medicine, American University of Beirut, Beirut, Lebanon
dc.contributor.affiliation Shamaa, F., Department of Anatomy, Cell Biology and Physiology, Faculty of Medicine, American University of Beirut, Beirut, Lebanon
dc.contributor.affiliation Ashoor, A., Functional Lipidomics Branch, Department of Pharmacology, Faculty of Medicine and Health Sciences, UAE University, Al Ain, United Arab Emirates
dc.contributor.affiliation El-Agnaf, O.M., Department of Biochemistry, Faculty of Medicine and Health Sciences, UAE University, Al Ain, United Arab Emirates, Faculty of Medicine, King Abdel Aziz University, Jeddah, Saudi Arabia
dc.contributor.affiliation Saadé, N.E., Department of Anatomy, Cell Biology and Physiology, Faculty of Medicine, American University of Beirut, Beirut, Lebanon
dc.contributor.authorAddress Safieh-Garabedian, B.; Department of Natural Sciences and Public Health, Zayed University, Abu Dhabi, United Arab Emirates; email: bared.garabedian@zu.ac.ae
dc.contributor.authorCorporate University: American University of Beirut Medical Center; Faculty: Faculty of Medicine; Department: Anatomy, Cell Biology and Physiological Sciences;
dc.contributor.authorDepartment Anatomy, Cell Biology and Physiological Sciences
dc.contributor.authorDivision
dc.contributor.authorEmail bared.garabedian@zu.ac.ae
dc.contributor.authorFaculty Faculty of Medicine
dc.contributor.authorInitials Safieh-Garabedian, B
dc.contributor.authorInitials Oz, M
dc.contributor.authorInitials Bey, RM
dc.contributor.authorInitials Shamaa, F
dc.contributor.authorInitials Ashoor, A
dc.contributor.authorInitials El-Agnaf, OM
dc.contributor.authorInitials Saade, NE
dc.contributor.authorOrcidID
dc.contributor.authorReprintAddress Safieh-Garabedian, B (reprint author), Zayed Univ, Dept Nat Sci and Publ Hlth, Abu Dhabi, U Arab Emirates.
dc.contributor.authorResearcherID
dc.contributor.authorUniversity American University of Beirut Medical Center
dc.description.cited Allan SM, 2001, NAT REV NEUROSCI, V2, P734, DOI 10.1038-35094583; Andersson U, 2012, ANNU REV IMMUNOL, V30, P313, DOI 10.1146-annurev-immunol-020711-075015; Austin PJ, 2010, J NEUROIMMUNOL, V229, P26, DOI 10.1016-j.jneuroim.2010.08.013; Barada KA, 2007, CYTOKINE, V37, P236, DOI 10.1016-j.cyto.2007.04.005; Bernik TR, 2002, J EXP MED, V195, P781, DOI 10.1084-jem.20011714; Bertrand D, 2007, BIOCHEM PHARMACOL, V74, P1155, DOI 10.1016-j.bcp.2007.07.011; Borovikov L, 2000, NATURE, V405, P462; Cartmell T, 2003, J PHYSIOL-LONDON, V549, P653, DOI 10.1113-jphysiol.2002.037291; Chatterjee PK, 2009, AM J PHYSIOL-CELL PH, V297, pC1294, DOI 10.1152-ajpcell.00160.2009; Chernyavsky AI, 2010, INT IMMUNOPHARMACOL, V10, P308, DOI 10.1016-j.intimp.2009.12.001; CHOI Y, 1994, PAIN, V59, P369; COLPAERT FC, 1982, LIFE SCI, V31, P67, DOI 10.1016-0024-3205(82)90402-7; Colville-Nash Paul, 2003, Methods Mol Biol, V225, P181; Conejero-Goldberg C, 2008, NEUROSCI BIOBEHAV R, V32, P693, DOI 10.1016-j.neubiorev.2007.10.007; Cunningham C, 2005, J NEUROSCI, V25, P9275, DOI 10.1523-JNEUROSCI.2614-05.2005; daCosta CJB, 2011, J NEUROSCI, V31, P13870, DOI 10.1523-JNEUROSCI.2652-11.2011; Dani JA, 2007, ANNU REV PHARMACOL, V47, P699, DOI 10.1146-annurev.pharmtox.47.120505.105214; Decosterd I, 2000, PAIN, V87, P149, DOI 10.1016-S0304-3959(00)00276-1; de Jonge WJ, 2005, NAT IMMUNOL, V6, P844, DOI 10.1038-ni1229; de Jonge WJ, 2007, BRIT J PHARMACOL, V151, P915, DOI 10.1038-sj.bjp.0707264; Galitovskiy V, 2011, J IMMUNOL, V187, P2677, DOI 10.4049-jimmunol.1002711; Haberberger RV, 2004, AUTON NEUROSCI-BASIC, V113, P32, DOI 10.1016-j.autneu.2004.05.008; HARGREAVES K, 1988, PAIN, V32, P77, DOI 10.1016-0304-3959(88)90026-7; Hernandez CM, 2010, J NEUROSCI, V30, P2442, DOI 10.1523-JNEUROSCI.5038-09.2010; Hosur V, 2011, MOL PHARMACOL, V79, P167, DOI 10.1124-mol.110.066381; Hurst R, 2013, PHARMACOL THERAPEUT, V137, P22, DOI 10.1016-j.pharmthera.2012.08.012; Ito H, 2004, GASTROENTEROLOGY, V126, P989, DOI 10.1053-j.gastro.2004.01.012; Kanaan SA, 1996, PAIN, V66, P373, DOI 10.1016-0304-3959(96)03068-0; Lee CH, 2011, BIOCHEM PHARMACOL, V82, P959, DOI 10.1016-j.bcp.2011.06.044; Li JH, 2011, J NEUROIMMUNOL, V239, P37, DOI 10.1016-j.jneuroim.2011.08.007; Loram LC, 2010, BRAIN BEHAV IMMUN, V24, P959, DOI 10.1016-j.bbi.2010.03.008; Ma DL, 2003, AM J PHYSIOL-REG I, V284, pR1323, DOI 10.1152-ajpregu.00756.2002; Matsunaga K, 2001, J IMMUNOL, V167, P6518; McIntosh JM, 2009, BIOCHEM PHARMACOL, V78, P693, DOI 10.1016-j.bcp.2009.05.020; McMahon SB, 2005, EXP NEUROL, V192, P444, DOI 10.1016-j.expneurol.2004.11.001; Medhurst SJ, 2008, J PAIN, V9, P580, DOI 10.1016-j.jpain.2008.01.336; Mogg AJ, 2002, J PHARMACOL EXP THER, V302, P197, DOI 10.1124-jpet.302.1.197; Nathan C, 2010, CELL, V140, P871, DOI 10.1016-j.cell.2010.02.029; Oz M, 2004, J NEUROSCI METH, V137, P167, DOI 10.1016-j.jneumeth.2004.02.016; Oz M, 1998, MOL PHARMACOL, V54, P1106; Pacini A, 2010, PAIN, V150, P542, DOI 10.1016-j.pain.2010.06.014; Pezet S, 2006, ANNU REV NEUROSCI, V29, P507, DOI 10.1146-annurev.neuro.29.051605.112929; Rosas-Ballina M, 2009, MOL MED, V15, P195, DOI 10.2119-molmed.2009.00039; Rueter LE, 2003, PAIN, V103, P269, DOI 10.1016-S0304-3959(02)00455-4; Saade NE, 2008, BRAIN BEHAV IMMUN, V22, P245, DOI 10.1016-j.bbi.2007.08.002; Saade NE, 2010, PAIN, V149, P89, DOI 10.1016-j.pain.2010.01.014; Saade NE, 2003, NEUROSCIENCE, V119, P155, DOI 10.1016-S0306-4522(03)00072-1; Safieh-Garabedian B, 2002, BRIT J PHARMACOL, V136, P947, DOI 10.1038-sj.bjp.0704793; Safieh-Garabedian B, 2012, EXPERT OPIN THER TAR, V16, P1065, DOI 10.1517-14728222.2012.714773; Safieh-Garabedian B, 2011, NEUROPHARMACOLOGY, V60, P496, DOI 10.1016-j.neuropharm.2010.11.004; SAFIEHGARABEDIAN B, 1995, BRIT J PHARMACOL, V115, P1265; Safieh-Garabedian B, 2003, NEUROSCIENCE, V121, P865, DOI 10.1016-S0306-4522(03)00500-1; SANDS SB, 1993, BIOPHYS J, V65, P2614; SEGUELA P, 1993, J NEUROSCI, V13, P596; Singhal SK, 2007, NEUROPHARMACOLOGY, V52, P387, DOI 10.1016-j.neuropharm.2006.08.023; TAKTAK YS, 1991, J PHARM PHARMACOL, V43, P578; Van Westerloo DJ, 2006, GASTROENTEROLOGY, V130, P1822, DOI 10.1053-j.gastro.2006.02.022; Wang H, 2003, NATURE, V421, P384, DOI 10.1038-nature01339; Williams DK, 2011, BIOCHEM PHARMACOL, V82, P915, DOI 10.1016-j.bcp.2011.05.001; Woolf CJ, 1997, BRIT J PHARMACOL, V121, P417, DOI 10.1038-sj.bjp.0701148; Xin JP, 2011, BRAIN BEHAV IMMUN, V25, P820, DOI 10.1016-j.bbi.2010.08.004
dc.description.citedCount 1
dc.description.citedTotWOSCount 2
dc.description.citedWOSCount 2
dc.format.extentCount 12
dc.identifier.articleNo
dc.identifier.coden NRSCD
dc.identifier.pubmedID 23880090
dc.identifier.scopusID 84882789245
dc.identifier.url
dc.publisher.address THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
dc.relation.ispartofConference
dc.relation.ispartofConferenceCode
dc.relation.ispartofConferenceDate
dc.relation.ispartofConferenceHosting
dc.relation.ispartofConferenceLoc
dc.relation.ispartofConferenceSponsor
dc.relation.ispartofConferenceTitle
dc.relation.ispartofFundingAgency
dc.relation.ispartOfISOAbbr Neuroscience
dc.relation.ispartOfIssue
dc.relation.ispartOfPart
dc.relation.ispartofPubTitle Neuroscience
dc.relation.ispartofPubTitleAbbr Neuroscience
dc.relation.ispartOfSpecialIssue
dc.relation.ispartOfSuppl
dc.relation.ispartOfVolume 250
dc.source.ID WOS:000324847400042
dc.type.publication Journal
dc.subject.otherAuthKeyword Cytokines
dc.subject.otherAuthKeyword Inflammation
dc.subject.otherAuthKeyword NGF
dc.subject.otherAuthKeyword Nicotinic receptor antagonists
dc.subject.otherAuthKeyword Nicotinic receptors
dc.subject.otherAuthKeyword Nociceptive hyperactivity
dc.subject.otherChemCAS carrageenan, 9000-07-1, 9049-05-2, 9061-82-9, 9064-57-7
dc.subject.otherChemCAS interleukin 8, 114308-91-7
dc.subject.otherChemCAS nerve growth factor, 9061-61-4
dc.subject.otherIndex bungarotoxin receptor
dc.subject.otherIndex carrageenan
dc.subject.otherIndex endotoxin
dc.subject.otherIndex interleukin 10
dc.subject.otherIndex interleukin 6
dc.subject.otherIndex interleukin 8
dc.subject.otherIndex methyllycaconitine citrate
dc.subject.otherIndex nerve growth factor
dc.subject.otherIndex nicotinic receptor blocking agent
dc.subject.otherIndex peptide analog of thymulin
dc.subject.otherIndex synthetic peptide
dc.subject.otherIndex unclassified drug
dc.subject.otherIndex animal behavior
dc.subject.otherIndex animal experiment
dc.subject.otherIndex animal model
dc.subject.otherIndex animal tissue
dc.subject.otherIndex antiinflammatory activity
dc.subject.otherIndex article
dc.subject.otherIndex cholinergic activity
dc.subject.otherIndex cold sensitivity
dc.subject.otherIndex competitive inhibition
dc.subject.otherIndex controlled study
dc.subject.otherIndex cytokine production
dc.subject.otherIndex cytokine release
dc.subject.otherIndex drug receptor binding
dc.subject.otherIndex drug targeting
dc.subject.otherIndex electrode
dc.subject.otherIndex female
dc.subject.otherIndex hyperalgesia
dc.subject.otherIndex nociceptive stimulation
dc.subject.otherIndex nonhuman
dc.subject.otherIndex oocyte
dc.subject.otherIndex pain assessment
dc.subject.otherIndex priority journal
dc.subject.otherIndex rat
dc.subject.otherIndex stimulus response
dc.subject.otherIndex tactile stimulation
dc.subject.otherIndex Xenopus
dc.subject.otherIndex 1,2-bis (o-aminophenoxy) ethane-N,N,N′,N′-tetraacetic acid
dc.subject.otherIndex 4-(2-hydroxyethyl) piperazineethanesulfonic acid
dc.subject.otherIndex acetylcholine
dc.subject.otherIndex Ach
dc.subject.otherIndex analysis of variance
dc.subject.otherIndex ANOVA
dc.subject.otherIndex BAPTA
dc.subject.otherIndex cytokines
dc.subject.otherIndex ELISA
dc.subject.otherIndex endotoxin
dc.subject.otherIndex enzyme-linked immunosorbent assay
dc.subject.otherIndex ET
dc.subject.otherIndex HEPES
dc.subject.otherIndex hot plate
dc.subject.otherIndex HP
dc.subject.otherIndex ICV
dc.subject.otherIndex IL
dc.subject.otherIndex inflammation
dc.subject.otherIndex interleukin
dc.subject.otherIndex intracerebroventricular
dc.subject.otherIndex MBS
dc.subject.otherIndex methyllycaconitine citrate
dc.subject.otherIndex MLA
dc.subject.otherIndex modified Barth's solution
dc.subject.otherIndex nerve growth factor
dc.subject.otherIndex NGF
dc.subject.otherIndex nicotinic receptor antagonists
dc.subject.otherIndex nicotinic receptors
dc.subject.otherIndex nociceptive hyperactivity
dc.subject.otherIndex PAT
dc.subject.otherIndex paw withdrawal duration
dc.subject.otherIndex peptide analog of thymulin
dc.subject.otherIndex PWD
dc.subject.otherIndex reverse sequence of PAT
dc.subject.otherIndex rPAT
dc.subject.otherIndex α7-nAChR
dc.subject.otherIndex α7-nicotinic acetylcholine receptor
dc.subject.otherIndex alpha7 Nicotinic Acetylcholine Receptor
dc.subject.otherIndex Animals
dc.subject.otherIndex Anti-Inflammatory Agents
dc.subject.otherIndex Carrageenan
dc.subject.otherIndex Cold Temperature
dc.subject.otherIndex Cytokines
dc.subject.otherIndex Electrophysiological Processes
dc.subject.otherIndex Endotoxins
dc.subject.otherIndex Female
dc.subject.otherIndex Hot Temperature
dc.subject.otherIndex Motor Activity
dc.subject.otherIndex Oocytes
dc.subject.otherIndex Pain
dc.subject.otherIndex Pain Measurement
dc.subject.otherIndex Rats
dc.subject.otherIndex Rats, Sprague-Dawley
dc.subject.otherIndex Thymic Factor, Circulating
dc.subject.otherIndex Xenopus
dc.subject.otherKeywordPlus NERVE GROWTH-FACTOR
dc.subject.otherKeywordPlus NECROSIS-FACTOR-ALPHA
dc.subject.otherKeywordPlus INFLAMMATORY HYPERALGESIA
dc.subject.otherKeywordPlus NICOTINIC RECEPTORS
dc.subject.otherKeywordPlus NEUROPATHIC PAIN
dc.subject.otherKeywordPlus ALLOSTERIC MODULATION
dc.subject.otherKeywordPlus XENOPUS-OOCYTES
dc.subject.otherKeywordPlus VAGUS NERVE
dc.subject.otherKeywordPlus T-CELLS
dc.subject.otherKeywordPlus RAT
dc.subject.otherWOS Neurosciences


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search AUB ScholarWorks


Browse

My Account